An astonishing 68% of adults have damage in their discs, or cushions, between their cervical vertebrae. This is referred to as cervical disk degeneration. If you don’t have it now, you will likely get it unless you are involved in a neck mobility program. An early sign of this might be noticing a popping or… Read More »
We welcome comments, which users can leave at the end of any of our systematic story reviews or at the end of any of our blog posts. But before leaving a comment, please review these notes about our policy. You are responsible for any comments you leave on this site. This site is primarily a… Read More »
The Podcast by KevinMD | Podcast | March 9, 2021 “When we think about holistic medicine, many assume that it requires human-to-human touch points and, therefore, doesn’t lend itself well to technology and innovations such as artificial intelligence. In fact, holistic medicine and whole-person care advocates often view technology as manufactured or impersonal and therefore… Read More »
D. Todd Detar, DO Q. What attracted you to medicine? A. While studying health education at the University of Delaware, a college sports injury ended my life’s dream of becoming an NFL player. One of my coaches saw an opportunity for me to work as a trainer for the Philadelphia Phillies, and over time, I… Read More »
Advertisements The regenerative medicine market is booming right now. Its global valuation is expected to reach $ 48.97 billion USD by the year 2025. Never heard of this type of medicine before? Not sure what it is or whether it’s a good option for you? If you have questions about it, you’ve come to the… Read More »
The news: Patients have started to receive the first antibody drug developed specifically to treat covid-19. It’s being tested in 32 patients at various doses in hospitals in the US. If it’s shown to be safe, the drug, referred to as LY-CoV555, will be studied in non-hospitalized coronavirus patients later this summer. The big idea:… Read More »
Print this page TARRYTOWN, N.Y. and PARIS, May 26, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not… Read More »